Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Investments and Licenses - Schedule of Pro Forma (Details)

v3.5.0.2
Acquisitions, Investments and Licenses - Schedule of Pro Forma (Details) - Transition Therapeutics - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Business Acquisition [Line Items]        
Revenues $ 298,035 $ 143,034 $ 946,172 $ 215,547
Net income (loss) (16,897) 124,942 (18,147) (51,089)
Net income (loss) attributable to common shareholders $ (16,897) $ 124,942 $ (18,147) $ (49,689)